Peptides Vietnam LogoPeptides Vietnam
Back to Guides
Science & HistoryUpdated Apr 2026

The Complete History of Peptide Research: A 100-Year Scientific Timeline

Peptides aren't new. Peptide-based medicine has over 100 years of clinical history, with the first peptide drug — insulin — saving lives since 1923. Today, more than 80 peptide drugs have received FDA approval, and over 150 are in clinical trials.

100+

Years of research

80+

FDA-approved drugs

150+

Drugs in clinical trials

What Are Peptides?

Peptides are short chains of amino acids — typically between 2 and 50 amino acids linked together. When the chain exceeds roughly 50 amino acids, it's generally classified as a protein. Your body produces thousands of peptides naturally, where they function as:

Hormones

Insulin, glucagon, oxytocin

Neurotransmitters

Endorphins

Signaling molecules

Growth factors, cytokines

Antimicrobial agents

Defensins

Key distinction: Peptide drugs are not the same as anabolic steroids, SARMs, or unregulated supplements. Many peptides are FDA-approved pharmaceuticals used in hospitals worldwide.

The Complete Peptide Research Timeline

1920s — The Insulin Revolution
1921

Frederick Banting and Charles Best isolate insulin from canine pancreatic extracts at the University of Toronto — the first peptide hormone ever isolated.

1922

Leonard Thompson, a 14-year-old diabetic, becomes the first human to receive insulin injections. His blood sugar normalizes. The era of peptide medicine begins.

1923

Eli Lilly begins commercial production of insulin. Banting and J.J.R. Macleod receive the Nobel Prize in Physiology or Medicine.

Why this matters:Insulin is a 51-amino-acid peptide. It remains one of the most widely used medications on Earth, with over 100 million users globally. The "peptides are experimental" narrative ignores a century of insulin's proven safety.

Source: Bliss, M. (2007). The Discovery of Insulin. University of Chicago Press. | Nobel Prize Archive (1923)

1930s–1950s — Mapping the Peptide Landscape
1932

Oxytocin is identified as a peptide hormone responsible for uterine contractions and milk ejection.

1953

Vincent du Vigneaud synthesizes oxytocin in the laboratory — the first peptide hormone ever synthesized. He receives the Nobel Prize in Chemistry (1955).

1953

Frederick Sanger determines the complete amino acid sequence of insulin, proving that proteins have defined structures. Another Nobel Prize followed in 1958.

1954

Synthetic oxytocin (Pitocin) enters clinical use for labor induction — still used in hospitals today.

Source: du Vigneaud, V., et al. (1953). Journal of the American Chemical Society. | Sanger, F. (1959). Nobel Lecture.

1960s–1970s — The GLP-1 Story Begins
1964

Researchers observe that oral glucose produces a stronger insulin response than intravenous glucose. Something in the gut is amplifying insulin release — they call this the "incretin effect."

1970s

Scientists identify GIP (glucose-dependent insulinotropic polypeptide) as one incretin hormone.

1979

GLP-1 (glucagon-like peptide-1) is identified when researchers sequence the proglucagon gene.

1987

The Holst laboratory in Copenhagen demonstrates that GLP-1 potently stimulates insulin secretion in humans — the foundational discovery behind Ozempic, Mounjaro, and Retatrutide.

Source: Holst, J.J. (2007). Physiological Reviews, 87(4), 1409-1439.

1980s — BPC-157 and the Healing Peptides
1980s

Croatian researchers at the University of Zagreb begin investigating Body Protection Compound (BPC), a sequence derived from human gastric juice.

1991

First published study on BPC-157 demonstrates its ability to accelerate wound healing in rats. Researchers note effects on angiogenesis and collagen synthesis.

1993–99

Multiple studies show BPC-157 accelerates healing of tendons, ligaments, muscles, and the gastrointestinal tract in animal models.

Research status: BPC-157 has never completed human clinical trials for FDA approval. However, it has over 100 published animal studies demonstrating safety and efficacy.

Source: Sikiric, P., et al. (1993). Journal of Physiology-Paris, 87(5), 313-327.

2000s — GLP-1 Drugs Enter the Market
2005

Exenatide (Byetta) becomes the first GLP-1 receptor agonist approved by the FDA for type 2 diabetes. Derived from Gila monster saliva (exendin-4).

2010

Liraglutide (Victoza) receives FDA approval. A modified human GLP-1 analog requiring only once-daily injection.

2014

Liraglutide (Saxenda) becomes the first GLP-1 approved specifically for weight loss in non-diabetics.

2017

Semaglutide (Ozempic) receives FDA approval for diabetes, requiring only once-weekly injection due to its long half-life.

2020s — The GLP-1 Revolution
2021

Semaglutide (Wegovy) receives FDA approval for chronic weight management. The STEP trials show average weight loss of 15% of body weight — unprecedented for any medication.

2022

Tirzepatide (Mounjaro) receives FDA approval as the first dual GLP-1/GIP receptor agonist, showing up to 22.5% weight loss in trials.

2023

Retatrutide Phase 2 trial results published. As a triple agonist (GLP-1 + GIP + Glucagon), it produces 28.7% average body weight loss — the highest ever recorded in clinical trials.

2024

Retatrutide enters Phase 3 clinical trials. Multiple other triple agonists enter development.

Source: Jastreboff, A.M., et al. (2023). New England Journal of Medicine, 389(6), 514-526.

80+ FDA-Approved Peptide Drugs

The claim that peptides are "unproven" ignores the extensive regulatory history. As of 2024, the FDA has approved more than 80 peptide-based drugs across multiple therapeutic categories:

CategoryExamplesApproval Years
Diabetes / MetabolismInsulin, Exenatide, Liraglutide, Semaglutide, Tirzepatide1923–2022
HormonalOxytocin, Vasopressin, Goserelin, Leuprolide1954–1990s
CardiovascularNesiritide, Eptifibatide1998–2001
OncologyOctreotide, Lanreotide, Degarelix1988–2008
Immune / InflammatoryCyclosporine, Enfuvirtide1983–2003
Bone / MetabolicTeriparatide, Abaloparatide2002–2017
GI / OtherLinaclotide, Plecanatide2012–2017

Currently in clinical trials: Over 150 peptide drugs are in various phases of FDA trials, including multiple next-generation GLP-1 combinations.

Research vs Approved: Understanding the Distinction

FDA-Approved Peptide Drugs

These have completed full human clinical trials and are prescribed by doctors:

Semaglutide (Ozempic, Wegovy)Tirzepatide (Mounjaro, Zepbound)Tesamorelin (Egrifta)Liraglutide (Saxenda, Victoza)

Research Peptides

Extensive animal data, limited human trials. Used in research and wellness communities:

BPC-157 — 100+ animal studiesTB-500 — Veterinary useGHK-Cu — Cosmetic/wound researchIpamorelin/CJC-1295 — GH research

Investigational (Currently in Human Trials)

Retatrutide — Phase 3Survodutide — Phase 3Cagrilintide — Phase 3

Why Sourcing Is the Real Concern

The science behind most popular peptides is solid. The problem is execution.

What the Research Proves

  • GLP-1 agonists produce significant, sustained weight loss
  • BPC-157 accelerates tissue healing in animal models
  • TB-500 promotes wound repair and angiogenesis
  • These mechanisms are well-understood

What the Research Cannot Guarantee

  • That the vial you receive contains what it claims
  • That the peptide was not degraded during shipping
  • That the concentration is accurate
  • That contaminants are absent

What to Look For in a Supplier

1

Third-party Certificate of Analysis (COA)

Batch-matched testing from an independent lab

2

Cold-chain shipping

Peptides degrade rapidly at room temperature — especially critical in Vietnam's climate

3

Transparent sourcing

Legitimate suppliers answer questions about their supply chain

4

Physician oversight

Not legally required everywhere, but strongly advisable for GLP-1 peptides

Frequently Asked Questions

Are peptides safe?

FDA-approved peptide drugs (insulin, semaglutide, tirzepatide) have extensive safety data from clinical trials involving tens of thousands of participants. Research peptides (BPC-157, TB-500) have strong animal safety data but limited human clinical trials. Sourcing quality is the primary safety variable.

How long have peptides been studied?

Peptide research began in the 1920s with insulin. GLP-1 research started in the 1960s–1980s. BPC-157 research began in the early 1990s. This represents 30–100 years of scientific investigation depending on the compound.

Why do people think peptides are new?

Social media discovered peptides around 2020–2023 when Ozempic became a cultural phenomenon. The science is decades old; the mainstream awareness is recent.

Are peptides legal in Vietnam?

Peptides exist in a regulatory gray area. They are not explicitly prohibited for personal use, though they are not approved as registered pharmaceuticals. Most users obtain them through research chemical suppliers or international sources.

What's the difference between pharmaceutical and research peptides?

Pharmaceutical peptides (Ozempic, Mounjaro) are manufactured under strict GMP conditions, prescribed by doctors, and covered by regulatory oversight. Research peptides are sold for "research purposes," vary in quality, and require the buyer to verify sourcing.

Conclusion

Peptides are not new. They are not experimental in the way social media implies. Insulin has been saving lives for over 100 years. GLP-1 science spans four decades. Even BPC-157 has 30+ years of published research.

The question has never been: "Do peptides work?"

The question is: "Who do you trust to source them?"

When evaluating peptide therapy, focus less on whether the science is "proven" — it largely is — and more on whether your supplier provides verifiable quality assurance.

Sources & References

  1. 1.Bliss, M. (2007). The Discovery of Insulin. University of Chicago Press.
  2. 2.Holst, J.J. (2007). The physiology of glucagon-like peptide 1. Physiological Reviews, 87(4), 1409-1439.
  3. 3.Sikiric, P., et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Current Pharmaceutical Design, 24(18), 1972-1989.
  4. 4.Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 389(6), 514-526.
  5. 5.Fosgerau, K., & Hoffmann, T. (2015). Peptide therapeutics: current status and future directions. Drug Discovery Today, 20(1), 122-128.
  6. 6.Drucker, D.J. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism, 27(4), 740-756.
  7. 7.Goldstein, A.L., et al. (2012). Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 12(S1), S37-S51.
  8. 8.FDA Drug Approval Database: accessdata.fda.gov
  9. 9.ClinicalTrials.gov — Retatrutide: NCT05929066

Verified Sourcing

Ready to Source Quality Peptides?

The science is clear. What matters now is sourcing. Peptara Labs provides third-party COA-verified peptides with cold-chain delivery throughout Vietnam, physician review included.

Visit Peptara Labs

Related Articles

Disclaimer: This content is for educational purposes only. It is not medical advice. Consult a healthcare professional before starting any peptide protocol.